ImmuneBridge
Building the next generation of cell therapies
San Francisco, United States · Founded 2022
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2022
- Business Model
- B2B
- Website
- immunebridge.com
- Last Round
- Seed
- Rounds
- 2
About
ImmuneBridge develops an integrated platform for designing and manufacturing next-generation cell therapies using umbilical cord blood-derived hematopoietic stem cells. The company's proprietary expansion technology amplifies immune stem cells while maintaining full multipotency, enabling rapid discovery and scalable production of natural killer (NK) cell therapies for hematologic malignancies and solid tumors. ImmuneBridge's machine learning-powered donor screening and manufacturing platform addresses key universal challenges in cell therapy development, targeting both academic and industry partners while building an internal pipeline of proprietary therapies.
Summary
ImmuneBridge is a Life Sciences company based in San Francisco, United States, founded in 2022. Investors include Insight Partners, M Ventures and Gaingels.
Tech & App Stack
3 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Unknown
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...